Clinical Trial News and Research

RSS

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients.

27 Jun 2014

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).

27 Jun 2014

Blocking enzyme Cdk5 could reduce brain damage after stroke

A drug that blocks the action of the enzyme Cdk5 could substantially reduce brain damage if administered shortly after a stroke, UT Southwestern Medical Center research suggests.

27 Jun 2014

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system.

26 Jun 2014

Response-adaptive randomization approach can boost patients’ participation in medical studies

It's a classic Catch-22: Medical researchers need to figure out if a promising new treatment is truly better than a current one, by randomly assigning half of a group of patients to get each treatment.

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

GW clinical trial aims to identify novel modalities to reduce seizures in MTLE patients

A first-of-its-kind clinical trial at the George Washington University Medical Faculty Associates employs low-frequency deep brain stimulation to potentially help reduce epileptic seizures in patients with mesial temporal lobe epilepsy (MTLE) - the most common type of focal epilepsy that often necessitates surgical resection of the temporal lobe, risking memory function.

26 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA).

25 Jun 2014

Addition of tomosynthesis to digital mammography increases cancer detection rate

The addition of tomosynthesis, a 3-dimensional breast imaging technique, to digital mammography in more than 170,000 examinations was associated with a decrease in the proportion of patients called back for additional imaging and an increase in the cancer detection rate, according to a study in the June 25 issue of JAMA.

25 Jun 2014

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford Health System has launched a clinical trial to investigate a new drug for the treatment of tinnitus, a chronic ringing of the head or ears that affects more than 600 million people worldwide.

25 Jun 2014

Duke enters into collaboration with BMS to promote open access to clinical information

Duke University, through its Duke Clinical Research Institute (DCRI), announced this week it has entered into a novel collaboration with Bristol-Myers Squibb (BMS) to promote open access to clinical information from company-sponsored studies.

25 Jun 2014

Paralyzed man can move fingers and hand with his own thoughts

For the first time ever, a paralyzed man can move his fingers and hand with his own thoughts thanks to an innovative partnership between The Ohio State University Wexner Medical Center and Battelle.

25 Jun 2014

Sclerosis patients treated with HSCT experience better long-term event-free survival

Among patients with a severe, life-threatening type of sclerosis, treatment with hematopoietic stem cell transplantation (HSCT), compared to intravenous infusion of the chemotherapeutic drug cyclophosphamide, was associated with an increased treatment-related risk of death in the first year, but better long-term survival, according to a study in the June 25 issue of JAMA.

25 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

Clinical Trial News and Research

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

Blocking enzyme Cdk5 could reduce brain damage after stroke

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Response-adaptive randomization approach can boost patients’ participation in medical studies

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

GW clinical trial aims to identify novel modalities to reduce seizures in MTLE patients

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Addition of tomosynthesis to digital mammography increases cancer detection rate

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Duke enters into collaboration with BMS to promote open access to clinical information

Paralyzed man can move fingers and hand with his own thoughts

Sclerosis patients treated with HSCT experience better long-term event-free survival

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

RYGB surgery can help reduce heart disease risk in obese patients with Type 2 diabetes

Trevena's Phase 1b data for TRV130 published in the journal Pain

Computer analysis of family photos could help diagnose rare genetic disorders

Researchers devise kinder, gentler way to measure newborns

Viewpoints: Concerns about ACOs; problems in Va. gov.'s strategy; Medicaid 'black hole'

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery